By A naturally derived sweetener may hold unexpected promise in the fight against hair loss, according to new research exploring improved delivery methods for existing treatments.
Scientists studying therapies for androgenetic alopecia—a condition affecting up to half of men and women—have identified a compound from the Stevia rebaudiana that could enhance the performance of Minoxidil, one of the most widely used medications for the condition, writes Popular Mechanics.
Minoxidil, originally developed to treat high blood pressure, has long been used to stimulate hair growth by influencing hormone pathways and encouraging follicle activity. But its effectiveness is often constrained by how poorly it dissolves in water and how difficult it is for the drug to penetrate the skin. To compensate, some patients and clinicians turn to microneedling—using tiny needles to create small punctures in the skin—to improve absorption and activate growth factors.
Researchers from China and Australia have now taken that concept further by developing a dissolving microneedle patch that incorporates stevioside, a natural compound extracted from stevia. Their findings, published in Advanced Healthcare Materials in 2025, suggest the compound may help overcome key limitations in how minoxidil is delivered.
“Using STV as a novel solubilizing agent, we incorporated minoxidil into a dissolving microneedle patch, which was used to enhance the solubility and bioavailability of minoxidil and overcome the limitations of traditional carrier single-function approaches,” the study authors wrote. “This method not only enhances drug penetration into skin but also eliminates other issues associated with traditional topical formulations, such as slow onset of action and/or inaccurate dosing.”
In laboratory testing on mice with hair loss conditions, the new patch produced markedly stronger results than conventional treatments. After 35 days, hair regrowth covered roughly two-thirds of the treated area in the experimental group, compared to about one-quarter in those receiving standard approaches.
The treatment targets a central biological process behind pattern baldness. The enzyme 5α-reductase converts testosterone into dihydrotestosterone (DHT), a hormone linked to the shrinking and eventual loss of hair follicles. Minoxidil works in part by counteracting these effects, and the new delivery system appears to improve how effectively the drug reaches its target.
Despite the encouraging results, researchers emphasize that findings in animal models do not always translate directly to humans. Differences in hair growth cycles and the complex causes of hair loss mean further testing is necessary.
“While the mouse model results are promising, human hair growth cycles differ, and androgenetic alopecia is influenced by multiple factors,” said Lifeng Kang, a co-author of the study. “Therefore, clinical trials are essential to confirm efficacy and safety in humans.”
The global market for hair loss treatments is already valued in the billions, reflecting widespread demand for more effective solutions. If future trials confirm these early findings, the stevioside-based microneedle patch could represent a more efficient and user-friendly alternative to existing therapies.
For now, the approach remains experimental, but it underscores a broader trend in biomedical research: revisiting familiar, naturally derived compounds for new therapeutic uses.
